|
[1]COROUGE M, MALLET V, VALLET-PICHARD A, et al.Increasing incidence of autoimmune hepatitis[J].J Hepatol, 2013, 58:s229-s407.
|
|
[2]SCHRAMM C, LOHSE AW.Autoimmune hepatitis on the rise[J].J Hepatol, 2014, 60 (3) :478-479.
|
|
[3]van GERVEN NM, de BORE YS, MULDER CJ, et al.Autoimmune hepatitis[J].World J Gastroenterol, 2016, 22 (19) :4651-4661.
|
|
[4]MANNS MP, LOHSE AW, VERGANI D.Autoimmune hepatitis-Update 2015[J].J Hepatol, 2015, 62 (1 Suppl) :s100-s111.
|
|
[5]LOHSE AW, MIELI-VERGANI G.Autoimmune hepatitis[J].J Hepatol, 2011, 55 (1) :171-182.
|
|
[6]LIBERAL R, VERGANI D, MIELI-VERGANI G.Paediatric autoimmune liver disease[J].Dig Dis, 2015, 33 (Suppl 2) :36-46.
|
|
[7]JUNGE N, TIEDAU M, VERBOOM M, et al.Human leucocyte antigens and pediatric autoimmune liver disease:Diagnosis and prognosis[J].Eur J Pediatr, 2016, 175 (4) :527-537.
|
|
[8]PNIEWSKA A, SOBOLEWSKA-PILARCZYK M, PAWLOWSKA M.Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children[J].Prz Gastroenterol, 2016, 11 (1) :18-23.
|
|
[9]European Association for the Study of the Liver.EASL clinical practice guidelines:Autoimmune hepatitis[J].J Hepatol, 2015, 63 (4) :971-1004.
|
|
[10]PERINI L, FRANCESCHET, CAZZAGON N, et al.Autoimmune hepatitis:clinical, laboratory and survival analysis in children and adults[J].J Hepatol, 2016, 64 (2) :s633.
|
|
[11]ZIZZO AN, VALENTINO PL, SHAH PS, et al.Second-line agents in pediatric patients with autoimmune hepatitis:A systematic review and meta-analysis[J].J Pediatr Gastroenterol Nutr, 2017, 65 (1) :6-15.
|
|
[12]KOSTYRKO O, SHUMILOV P, SHIGOLEVA N.Mycophenolate mofetil for the treatment of autoimmune hepatitis in children[J].J Hepatol, 2016, 64:s631-s832.
|
|
[13]DIESTELHORST J, JUNGE N, SCHLUE J, et al.Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy[J].PLo S One, 2017, 12 (7) :e0181107.
|
|
[14]DANIELSSON BORSSEN A, WALLERSTEDT S, NYHLIN N, et al.Pregnancy and childbirth in women with autoimmune hepatitis is safe, even in compensated cirrhosis[J].Scand J Gastroenterol, 2016, 51 (4) :479-485.
|
|
[15]MENDIZABAL M, MARCIANO S, VIDELA MG, et al.Fulminant presentation of autoimmune hepatitis:Clinical features and early predictors of corticosteroid treatment failure[J].Eur J Gastroenterol Hepatol, 2015, 27 (6) :644-648.
|
|
[16]PARKER R, OO YH, ADAMS DH.Management of patients with difficult autoimmune hepatitis[J].Ther Adv Gastroenterol, 2012, 5 (6) :421-437.
|
|
[17]WESTBROOK RH, DUSHEIKO G, WILLIAMSON C.Pregnancy and liver disease[J].J Hepatol, 2016, 64 (4) :933-945.
|
|
[18]LAMMERT C, LOY VM, OSHIMA K, et al.Management of difficult cases of autoimmune hepatitis[J].Curr Gastroenterol Rep, 2016, 18 (2) :9.
|
|
[19]MCFARLANE IG, HENEGHAN MA.Autoimmunity and the female liver[J].Hepatol Res, 2004, 28 (4) :171-176.
|
|
[20]MONTANON-LOZA AJ, CARPENTER HA, CZAJA AJ.Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis[J].Am J Gastroenterol, 2008, 103 (8) :1944-1951.
|
|
[21]AL-CHALABI T, UNDERHILL JA, PORTMANN BC, et al.Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis[J].J Hepatol, 2008, 48 (1) :140-147.
|
|
[22]DONET JA, PERLINI EF, GILINSKY D, et al.Impact of gender on clinical presentation, response to treatment, and long-term outcomes in an ethnically diverse population of patients with autoimmune hepatitis[J].J Hepatol, 2016, 64:s425-s630.
|
|
[23]STRASSBURG CP, MANNS MP.Autoimmune hepatitis in the elderly:What is the difference?[J].J Hepatol, 2006, 45 (4) :480-482.
|
|
[24]MURATORI P, LALANNE C, BARBATO E, et al.Features and progression of asymptomatic autoimmune hepatitis in italy, clinical gastroenterology and hepatology[J].Clin Gastroenterol Hepatol, 2016, 14 (1) :139-146.
|
|
[25]VISSEREN T, DARWISH MURAD S.Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation[J].Best Pract Res Clin Gastroenterol, 2017, 31 (2) :187-198.
|
|
[26]PADILLA M, MAYORGA R, CARRASCO F, et al.Liver transplantation for autoimmune hepatitis in Peru:Outcomes and recurrence[J].Ann Hepatol, 2012, 11 (2) :222-227.
|
|
[27]van GERVEN NM, VERWER BJ, WITTE BI, et al.Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission[J].J Hepatol, 2013, 58 (1) :141-147.
|
|
[28]FAISAL N, RENNER EL.Recurrence of autoimmune liver diseases after liver transplantation[J].World J Hepatol, 2015, 7 (29) :2896-2905.
|
|
[29]SRIVASTAVA S, BOYER JL.Psychological stress is associated with relapse in type 1 autoimmune hepatitis[J].Liver Int, 2010, 30 (10) :1439-1447.
|
|
[30]BAIRY I, BERWAL A, SESHADRI S.Autoimmune hepatitisprimary biliary cirrhosis overlap syndrome[J].J Clin Diagn Res, 2017, 11 (7) :od07-od09.
|
|
[31]NGUY EN HH, SHAHEEN AA.Development of a multivariate model using serum biomarkers to better define primary biliary cholangitis (PBC) -autoimmune hepatitis (AIH) overlap syndrome[J].J Hepatol, 2017, 66:s333-s542.
|
|
[32]PARK Y, CHO Y, CHO EJ, et al.Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea:Characteristics, treatments, and outcomes[J].Clin Mol Hepatol, 2015, 21 (2) :150-157.
|
|
[33]WARLING O, BOVY C, COIMBRA C.Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis[J].World J Gastroenterol, 2014, 20 (16) :4811-4816.
|
|
[34]ZHANG HW, LI SN.A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBCAIH-overlap synrome:Evidence from 97 monotherapy and 117combinations[J].Prz Gastroenterol, 2015, 10 (3) :148-155.
|
|
[35]ZENOUZI R, LOHSE AW.Long-term outcome in PSC/AIH‘overlap syndrome’:Does immunosuppression also treat the PSC component?[J].J Hepatol, 2014, 61 (5) :1189-1191.
|
|
[36]de BOER YS, KOSINSKI AS, URBAN TJ, et al.Features of autoimmune hepatitis in patients with drug-induced liver injury[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :103-112.
|
|
[37]AIZAWA Y, HOKARI A.Autoimmune hepatitis:Current challenges and future prospects[J].Clin Exp Gastroenterol, 2017, 10:9-18.
|
|
[38]LICATA A, MAIDA M, CABIBI D, et al.Clinical features and outcomes of patients with drug-induced autoimmune hepatitis:A retrospective cohort study[J].Dig Liver Dis, 2014, 46 (12) :1116-1120.
|
|
[39]TAKEDA K, ODA M, OKADA T, et al.Over-the-counter drug induced autoimmune hepatitis[J].Intern Med, 2016, 55 (10) :1293-1297.
|
|
[40]OH HJ, MOK YM, BAEK MS.Co-development of autoimmune hepatitis and Sj9gren's syndrome triggered by the administration of herbal medicines[J].Clin Mol Hepatol, 2013, 19 (3) :305-308.
|
|
[41]THULUVATH PJ, WAGENNAR RR, VERMA S.Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation:A case-control study[J].Arch Med Sci, 2015, 11 (6) :1227-1235.
|
|
[42]KRSHNAMOORTHY TL, MIEZYNSKA-KURTYCZ J, HODSON J, et al.Long term low dose steroid triple immunosuppressive regimens in post transplant autoimmune hepetitis (AIH) patients reduces the incidence of recurrent disease and is not associated with increased mortality[J].J Hepatol, 2015, 62:s263-s864.
|
|
[43]XU YT, LIU DJ, MENG FY, LI GB, et al.Possible benefit of splenectomy in liver transplantation for autoimmune hepatitis[J].Hepatobiliary Pancreat Dis Int, 2014, 13 (3) :328-331.
|
|
[44]CARBONE M, NEUBERGER JM.Autoimmune liver disease, autoimmunity and liver transplantation[J].J Hepatol, 2014, 60 (1) :210-223.
|
|
[45]CZAJA AJ.Autoantibody-negative autoimmune hepatitis[J].Dig Dis Sci, 2012, 57 (3) :610-624.
|
|
[46]WANG XQ, JIANG WJ, MIAO Q, et al.Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients:A single center experience[J].J Dig Dis, 2013, 14 (4) :175-180.
|
DownLoad: